Cumberland receives FDA approval for expanded Caldolor injection

Cumberland (CPIX) has received approval from the FDA for an expanded indication for its Caldolor – ibuprofen – Injection product. The indication now includes the management of postoperative pain, and the approval coincides with the launch of a newly designed website for healthcare professionals highlighting this advancement and the evolving role of non-opioid pain management. With this update, Caldolor is indicated for use in adult and pediatric patients ages 3 months and older for: management of mild to moderate pain, including postoperative pain; management of moderate to severe pain, including postoperative pain, as an adjunct to opioid analgesics; reduction of fever. The newly launched Caldolor website aligns with this expanded indication, featuring dedicated content on postoperative pain management and the importance of multimodal, opioid-sparing approaches.